Consun Pharmaceutical Group Ltd. Annual Results: Standalone & Consolidated Reports

Annual Results

Results Snapshot

Figures in Million

Consolidate Annual Results

Dec'25

Dec'24

Dec'23

Dec'22

Dec'21

Dec'20

Dec'19

Net Sales

3,706.20

3,217.15

2,862.07

2,720.73

2,464.25

1,969.64

1,959.70

Other Operating Income

0.00

Total Operating income

3,706.20

3,217.15

2,862.07

2,720.73

2,464.25

1,969.64

1,959.70

Raw Material Cost

813.65

786.21

738.62

670.68

623.48

484.49

529.37

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

735.97

643.13

534.28

518.26

441.10

319.06

345.56

Power Cost

0.00

Manufacturing Expenses

4.73

26.98

23.50

12.71

15.55

24.05

32.93

Selling and Distribution Expenses

1,480.97

1,287.11

1,156.57

1,098.26

939.82

777.26

788.82

Other Expenses

-57.60

-56.44

-43.78

-39.43

-33.35

-24.91

-29.30

Total Expenditure (Excl Depreciation)

2,459.29

2,179.08

2,015.13

1,905.62

1,686.43

1,355.76

1,403.66

Operating Profit (PBDIT) excl Other Income

1246.9

1038.1

846.9

815.1

777.8

613.9

556

Other Income

53.34

95.01

130.94

65.57

76.39

66.10

-1.73

Operating Profit (PBDIT)

1,371.93

1,201.93

1,063.63

968.90

941.58

760.07

636.59

Interest

4.73

26.98

23.50

12.71

15.55

24.05

32.93

Exceptional Items

3.76

0.00

-369.81

Gross Profit (PBDT)

2,892.55

2,430.94

2,123.45

2,050.05

1,840.76

1,485.15

1,430.33

Depreciation

71.68

68.85

85.74

88.22

87.36

80.08

82.28

Profit Before Tax

1,299.28

1,106.09

954.39

867.96

838.66

655.94

151.56

Tax

116.36

111.38

85.25

72.91

131.06

114.61

79.99

Provisions and contingencies

0.00

Profit After Tax

1,169.19

987.14

866.91

794.14

711.28

560.48

90.51

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

1,169.19

987.14

866.91

794.14

711.28

560.48

90.51

Share in Profit of Associates

0.00

Minority Interest

12.00

7.50

2.23

0.92

-3.68

-19.15

-18.93

Other related items

0.00

Consolidated Net Profit

1,181.19

994.64

869.14

795.06

707.60

541.33

71.58

Equity Capital

0.00

Face Value

0.0

Reserves

5,051.18

4,360.72

3,992.80

3,531.17

3,202.15

2,632.56

2,230.57

Earnings per share (EPS)

1.37

1.19

1.08

1.0

0.88

0.69

0.11

Diluted Earnings per share

1.37

1.19

1.08

1.0

0.88

0.69

0.11

Operating Profit Margin (Excl OI)

33.64%

32.27%

29.59%

29.96%

31.56%

31.17%

28.37%

Gross Profit Margin

36.99%

36.52%

36.34%

35.14%

37.58%

37.37%

11.93%

PAT Margin

31.55%

30.68%

30.29%

29.19%

28.86%

28.46%

4.62%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Annual Analysis Highlights

Net Sales

YoY Growth in year ended Dec 2025 is 15.20% vs 12.40% in Dec 2024

Consolidate Net Profit

YoY Growth in year ended Dec 2025 is 18.76% vs 14.44% in Dec 2024

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Dec 2025 is 19.13% vs 18.68% in Dec 2024

Interest

YoY Growth in year ended Dec 2025 is -82.59% vs 14.89% in Dec 2024

Operating Profit Margin (Excl OI)

YoY Growth in year ended Dec 2025 has improved from Dec 2024

Compare Annual Results Of Consun Pharmaceutical Group Ltd. With

Select Peers

Figures in Million

Consolidate Annual Results

Change(HKD)

Change(%)

Net Sales

3,706.20

6,955.50

-3,249.30

-46.72%

Other Operating Income

0.00

Total Operating income

3,706.20

6,955.50

-3,249.30

-46.72%

Raw Material Cost

813.65

1,446.24

-632.59

-43.74%

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

735.97

881.17

-145.20

-16.48%

Power Cost

0.00

Manufacturing Expenses

4.73

251.27

-246.54

-98.12%

Selling and Distribution Expenses

1,480.97

2,143.12

-662.15

-30.90%

Other Expenses

-57.60

-92.00

34.40

37.39%

Total Expenditure (Excl Depreciation)

2,459.29

3,801.84

-1,342.55

-35.31%

Operating Profit (PBDIT) excl Other Income

1,246.91

3,153.66

-1,906.75

-60.46%

Other Income

53.34

48.02

5.32

11.08%

Operating Profit (PBDIT)

1,371.93

3,634.97

-2,263.04

-62.26%

Interest

4.73

251.27

-246.54

-98.12%

Exceptional Items

3.76

-600.30

604.06

100.63%

Gross Profit (PBDT)

2,892.55

5,509.26

-2,616.71

-47.50%

Depreciation

71.68

433.29

-361.61

-83.46%

Profit Before Tax

1,299.28

2,350.11

-1,050.83

-44.71%

Tax

116.36

299.39

-183.03

-61.13%

Provisions and contingencies

0.00

Profit After Tax

1,169.19

2,201.85

-1,032.66

-46.90%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

1,169.19

2,201.85

-1,032.66

-46.90%

Share in Profit of Associates

0.00

Minority Interest

12.00

-151.16

163.16

107.94%

Other related items

0.00

Consolidated Net Profit

1,181.19

2,050.68

-869.49

-42.40%

Equity Capital

0.00

Face Value

0.00

Reserves

5,051.18

8,737.04

-3,685.86

-42.19%

Earnings per share (EPS)

1.37

2.50

-1.13

-45.20%

Diluted Earnings per share

1.37

2.50

-1.13

-45.20%

Operating Profit Margin (Excl OI)

33.64%

45.34%

0.00

-11.70%

Gross Profit Margin

36.99%

40.02%

0.00

-3.03%

PAT Margin

31.55%

31.66%

0.00

-0.11%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Annual - Net Sales

Net Sales 370.62 Million

in Dec 2025

Figures in Million

YoY Growth in year ended Dec 2025 is 15.20% vs 12.40% in Dec 2024

Annual - Consolidate Net Profit

Consolidate Net Profit 118.12 Million

in Dec 2025

Figures in Million

YoY Growth in year ended Dec 2025 is 18.76% vs 14.44% in Dec 2024

Annual - Operating Profit (PBDIT)

Operating Profit (PBDIT) 131.86 Million

in Dec 2025

Figures in Million

YoY Growth in year ended Dec 2025 is 19.13% vs 18.68% in Dec 2024

Annual - Interest

Interest 0.47 Million

in Dec 2025

Figures in Million

YoY Growth in year ended Dec 2025 is -82.59% vs 14.89% in Dec 2024

Annual - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 33.64%

in Dec 2025

Figures in %

YoY Growth in year ended Dec 2025 has improved from Dec 2024